查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1542857

全球肌腱病市場 - 2024-2031

Global Tendinopathy Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

2023年，全球肌腱病市場規模達2,152.6億美元，預估至2031年將達2,991.6億美元，2024-2031年預測期間複合年成長率為4.2%。

肌腱病變被定義為以疼痛、腫脹和功能受損為特徵的肌腱退化。肌腱病變是指肌腱變得疼痛且活動範圍有限。肌腱病比肌腱炎更常見，它可能由多種原因引起，例如老化、壓力或受傷。

肌腱是將肌肉與骨頭連接起來的繩索狀組織。當肌腱受傷或過度使用時，就會出現肌腱病變。儘管肌腱病可能會變成慢性，但休息和物理治療可能會改善症狀。

市場動態：

司機

肌腱和運動相關損傷的發生率增加

全球肌腱病市場的需求是由多種因素所驅動的。肌腱病市場是由肌腱和運動相關損傷發生率的增加所推動的。這一趨勢很大程度上歸因於體育活動的增加、職業傷害和導致肌腱炎的生活方式的改變，特別是在運動員和老齡化人口中。

肌腱病的盛行率正在上升，有報告表明，每年有超過一百萬名運動員遭受肌腱相關損傷，佔運動傷害的很大一部分。隨著人們擴大參與體育運動和體育活動，這一趨勢進一步加劇，導致對有效治療方案的需求更高。根據 Sage Journals 2023 年 9 月發表的文章，肌腱損傷是一種常見的臨床問題，由過度使用、遺傳傾向、撕裂或老化引起。全球每年發生超過 3000 萬例肌腱損傷。

同樣，2023 年，國家安全委員會表示，有 370 萬人因運動和娛樂設備受傷而在急診室接受治療。同一消息來源稱，2022 年運動和娛樂傷害增加了 12%，這凸顯了活躍人群患肌腱炎的風險不斷增加。 2023 年，運動和娛樂傷害將增加 2%。

此外，投資等行業策略的關鍵參與者更加關注肌腱病的治療，這將推動該市場的成長。例如，2023 年2 月，格拉斯哥大學專門研究肌腱疾病的衍生公司Causeway Therapeutics 從投資者那裡籌集了875 萬英鎊，用於對其先導化合物TenoMIRa 治療外上髁炎（網球肘）進行國際2 期臨床試驗。

此外，2021 年 10 月，梅奧診所物理醫學和復健專家 Jeffrey S. Brault（DO）和 Jane Konidis（醫學博士）討論了兩種針對腕隧道症候群和肌腱病的微創治療方法。腕隧道鬆解和肌腱病變治療的新方法。

限制

高治療成本、與藥物相關的風險和毒性、人們缺乏認知、有效治療選擇有限以及監管挑戰等因素預計將阻礙市場。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 肌腱和運動相關損傷的發生率不斷增加
      • 科技不斷進步
    • 限制
      • 治療費用高
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析

第 6 章：依條件類型

  • 跟腱炎
  • 髕腱炎
  • 肩袖肌腱炎
  • 岡上肌腱炎
  • 其他條件

第 7 章：透過治療

  • 藥品類型
    • 非類固醇抗發炎藥
    • 皮質類固醇注射劑
  • 矯正器、夾板和支架
  • 其他

第 8 章：按通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 9 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 10 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 11 章：公司簡介

  • Zimmer Biomet
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • 3M
  • Stryker
  • Smith+Nephew
  • Ossur
  • Merck & Co., Inc.
  • Pfizer Inc
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • Abbott

第 12 章：附錄

簡介目錄
Product Code: PH8584

Overview

The global tendinopathy market reached US$ 215.26 billion in 2023 and is expected to reach US$ 299.16 billion by 2031 growing with a CAGR of 4.2% during the forecast period 2024-2031.

Tendinopathy is defined as tendon degeneration characterized by pain, swelling, and impaired performance. Tendinopathy is when a tendon becomes painful and has a limited range of motion. More common than tendonitis, tendinopathy can be caused by many things, like aging, stress, or injury.

Tendons are rope-like tissues that connect your muscles to your bones. Tendinopathy can develop when you injure or overuse a tendon. Although tendinopathy can become chronic, rest and physical therapy will likely improve symptoms.

Market Dynamics: Drivers

Increasing incidence of tendon and sports-related injuries

The demand for the global tendinopathy market is driven by multiple factors. The tendinopathy market is driven by an increasing incidence of tendon and sports-related injuries. This trend is largely attributed to a rise in sports activities, occupational injuries, and lifestyle changes that contribute to tendonitis, particularly among athletes and the aging population.

The prevalence of tendinopathy is rising, with reports indicating that athletes experience over a million tendon-related injuries annually, accounting for a significant portion of sports injuries. This trend is further exacerbated by the growing participation in sports and physical activities, leading to a higher demand for effective treatment options. As per Sage Journals publication in September 2023, tendon injuries are a common clinical problem that results from overuse, genetic predisposition, tears, or aging. More than 30 million tendon injuries occur annually worldwide.

Similarly, in 2023, the National Safety Council, stated that 3.7 million people were treated in emergency departments for injuries involving sports and recreational equipment. The same source, reported a 12% increase in sports and recreational injuries in 2022, highlighting the growing risk of tendonitis among active individuals The activities most frequently associated with injuries are exercise, cycling, and basketball. Sports and recreational injuries increase by 2% in 2023.

Moreover, key players in the industry strategies such as investments and more focus on the treatment of tendinopathy that would propel this market growth. For instance, in February 2023, Causeway Therapeutics, a University of Glasgow spin-out specializing in tendon disease raised £8.75 million from investors to conduct an international Phase 2 clinical trial of its lead compound, TenoMIRa in lateral epicondylitis (tennis elbow).

Also, in October 2021, Mayo Clinic Physical Medicine and Rehabilitation specialists Jeffrey S. Brault, D.O., and Jane Konidis, M.D., discuss two minimally invasive treatments for carpal tunnel syndrome and tendinopathy. New approaches to carpal tunnel release and treatment of tendinopathy.

Restraints

Factors such as high treatment costs, risk & toxicity associated with the drugs, lack of awareness among people, limited effective treatment options, and regulatory challenges are expected to hamper the market.

Segment Analysis

The global tendinopathy market is segmented based on condition type, treatment, distribution channels, and region.

The achilles tendinitis segment accounted for approximately 43.3% of the global tendinopathy market share

The achilles tendinitis segment is expected to hold the largest market share over the forecast period. The rise in sports activities, particularly among younger populations, has led to a corresponding increase in Achilles tendinitis cases. As more individuals engage in high-impact sports, the risk of developing this condition rises significantly driving this segment growth in the market.

Treatment modalities for Achilles tendinitis have evolved, with non-invasive options such as physical therapy, shockwave therapy, and regenerative therapies like platelet-rich plasma (PRP) injections gaining popularity. These treatments are preferred due to their effectiveness and lower recovery times compared to surgical options help to drive this market growth.

Moreover, key players in the industry more focus on research studies, investments in tendinopathy treatment, and key developments propel this segment in the market. For instance, in July 2022, a recent study in Physical Therapy in Sport found significant differences in strength and other fitness factors in those with Achilles tendinopathy compared to those without the condition. In addition to seeing a physical therapist to address Achilles pain, experts suggest focusing on calf-strengthening exercises, assessing your running schedule, and doing cross-training activities.

Similarly, in January 2023, NIH funded Penn Medicine's Achilles tendon research center for nearly $8M. The new Penn Achilles Tendinopathy Center of Research Translation seeks to build insights that lead to better treatment of Achilles tendon injuries.

Also, in July 2023, the Isokinetic Football Medicine Conference held May 25-27 in London revealed significant improvement in professional athletes with Achilles tendon injuries using a treatment of bio-inductive and multi-fractioned hyaluronic acid (HA) injections.

Geographical Analysis

North America accounted for approximately 42.8% of the global tendinopathy market share

North America region is expected to hold the largest market share over the forecast period owing to the high incidence of sports & occupational injuries driving this market growth in the region. According to the Science Direct in 2024, every year, there are more than 32 million acute and chronic tendon and ligament injuries that occur in the United States.

Moreover, the rising incidence of an aging population, well-established healthcare infrastructure, government initiatives such as awareness programs, and key player investments would drive this market growth. For instance, in January 2023, Zimmer Biomet Holdings, Inc. announced that it had reached a definitive agreement to acquire Embody, Inc., a privately-held medical device company focused on soft tissue healing, for $155 million at closing and up to an additional $120 million subject to achieving future regulatory and commercial milestones over three years.

In addition, a major number of key player's presence and product launches & approvals would propel this market growth in this region. For instance, in May 2021, Pendopharm launched SportVis, the first and only hyaluronic acid injection treatment that is clinically demonstrated and approved by Health Canada to relieve pain and restore function in damaged tendons and ligaments.

Also, in September 2021, Stryker introduced the new Citrelock Tendon Fixation Device System, which is designed to enable fixation without causing damage to the tendon during placement. The new system consists of a tendon thread with a resorbable technology called Citregen.

Market Segmentation

By Condition Type

  • Achilles Tendinitis
  • Patellar Tendinitis
  • Rotator Cuff Tendinitis
  • Supraspinatus Tendonitis
  • Other Conditions

By Treatment

  • Drug Type
    • NSAIDs
    • Corticosteroid Injections
  • Orthotics, Splints and Braces
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • The rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the tendinopathy market include Zimmer Biomet, 3M, Stryker, Smith+Nephew, Ossur, Merck & Co., Inc., Pfizer Inc., GSK plc., Johnson & Johnson Services, Inc., and Abbott among others.

Key Developments

  • In November 2022, Camber Pharmaceuticals launched generic Naprosyn. It is used to relieve pain from various conditions such as headaches, muscle aches, tendonitis, dental pain, and menstrual cramps.
  • In May 2022, CoNextions Inc. announced the first patient treated with CoNextions TR tendon repair system, a revolutionary tendon repair implant.
  • In April 2022, Boehringer Ingelheim launched RenuTend a new stem cell therapy to improve the healing of tendon and suspensory ligament injuries in horses.
  • In July 2021, Ossur launched the new Rebound Post-Op Elbow Brace, a non-invasive, lightweight adjustable brace with intuitive design features intended to optimize the fitting experience for clinicians as well as ease-of-use for patients who are recovering from severe elbow injury or surgical procedures.

Why Purchase the Report?

  • To visualize the global tendinopathy market segmentation based on condition type, treatment, distribution channels, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of the tendinopathy market with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in excel consisting of key products of all the major players.

The global tendinopathy market report would provide approximately 62 tables, 56 figures, and 183 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Condition Type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by Distribution Channels
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Incidence of Tendon and Sports-related Injuries
      • 4.1.1.2. Growing Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. High Treatment Costs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. By Condition Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition Type
    • 6.1.2. Market Attractiveness Index, By Condition Type
  • 6.2. Achilles Tendinitis *
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Patellar Tendinitis
  • 6.4. Rotator Cuff Tendinitis
  • 6.5. Supraspinatus Tendonitis
  • 6.6. Other Conditions

7. By Treatment

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Market Attractiveness Index, By Treatment
  • 7.2. Drug Type *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. NSAIDs
    • 7.2.4. Corticosteroid Injections
  • 7.3. Orthotics, Splints and Braces
  • 7.4. Others

8. By Distribution Channels

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 8.1.2. Market Attractiveness Index, By Distribution Channels
  • 8.2. Hospital Pharmacies *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Retail Pharmacies
  • 8.4. Online Pharmacies

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Zimmer Biomet *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. 3M
  • 11.3. Stryker
  • 11.4. Smith+Nephew
  • 11.5. Ossur
  • 11.6. Merck & Co., Inc.
  • 11.7. Pfizer Inc
  • 11.8. GSK plc
  • 11.9. Johnson & Johnson Services, Inc.
  • 11.10. Abbott

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us